• 1.

    Perera M, Krishnananthan N, Lindner U, Lawrentschuk N (2016) An update on focal therapy for prostate cancer. Nat Rev Urol 13(11):641–653

  • 2.

    Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A et al (2017) New and established technology in focal ablation of the prostate: a systematic review. Eur Urol 71(1):17–34

  • 3.

    Guillaumier S, Peters M, Arya M et al (2018) A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol 74(4):422–429

  • 4.

    Stabile A, Orczyk C, Hosking-Jervis F et al (2019) Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localised prostate cancer. BJU Int 124(3):431–440

  • 5.

    Mathew MS, Oto A (2017) MRI-guided focal therapy of prostate cancer. Future Oncol 13(6):537–549

  • 6.

    Sivaraman A, Barret E (2016) Focal therapy for prostate cancer: an “A la Carte” approach. Eur Urol 69(6):973–975

  • 7.

    Ganzer R, Arthanareeswaran VKA, Ahmed HU, Cestari A, Rischmann P, Salomon G et al (2018) Which technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statement. Prostate Cancer Prostatic Dis 21(2):175–186

  • 8.

    Blazevski A, Amin A, Scheltema MJ et al (2019) Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. doi.org/10.1111/bju.14951

  • 9.

    Blazevski A, Scheltema MJ, Yuen B, Masand N, Nguyen TV, Delprado W et al (2019) Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort. Eur Urol Onc. doi.org/10.1016/j.euo.2019.04.008

  • 10.

    Collettini F, Enders J, Stephan C, Fischer T, Baur ADJ, Penzkofer T et al (2019) Image-guided irreversible electroporation of localized prostate cancer: functional and oncologic outcomes. Radiology 292(1):250–257

  • 11.

    Le Nobin J, Rosenkrantz AB, Villers A, Orczyk C, Deng FM, Melamed J et al (2015) Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis. J Urol 194(2):364–370

  • 12.

    Shah TT, Peters M, Eldred-Evans D et al (2019) Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol 76:98–105

  • 13.

    Thompson J, Sridhar AN, Tan WS et al (2019) Pathological findings and magnetic resonance imaging concordance at salvage radical prostatectomy for local recurrence following partial ablation using high intensity focused ultrasound. J Urol 201(6):1134–1143

  • 14.

    Srougi V, Barret E, Nunes-Silva I, Baghdadi M, Garcia-Barreras S, Pierrat N et al (2017) Focal brachytherapy for localized prostate cancer: urinary toxicity depends on tumor location. Brachytherapy 16(5):988–992

  • 15.

    Cosset JM, Cathelineau X, Wakil G, Pierrat N, Quenzer O, Prapotnich D et al (2013) Focal brachytherapy for selected low-risk prostate cancers: a pilot study. Brachytherapy 12(4):331–337

  • 16.

    Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG et al (2017) Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 18(2):181–191

  • 17.

    Gill IS, Azzouzi AR, Emberton M et al (2018) Randomised trial of partial gland ablation with vascular targeted photodynamic versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness. J Urol 200(4):786–793

  • 18.

    Noweski A, Roosen A, Labdai S et al (2019) Medium-term follow-up of vascular-targeted photodynamic therapy of localised prostate cancer using TOOKAD soluble WST-11 (phase II trials). Eur Urol Focus 5:1022–1028

  • 19.

    Valerio M, Dickinson L, Ali A et al (2017) Nanoknife electroporation ablation tiral: a prospective development study investigating focal irreveribsle electropiraiton for localised prostate cancer. J Urol 197(3):647–654

  • 20.

    Tay KJ, Scheltema MJ, Ashmed HU et al (2017) Patient selection for prostate focal therapy in the era of active surveillance: an international Delphi Consenses Project. Prostate Cancer Prostatic Dis 20:294–299

  • 21.

    King MT, Nguyen PL, Boldbaatar N et al (2018) Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer 124(17):3528–3535

  • Source link